Medicinal Genomics
Stephen McLaughlin has extensive experience in bioinformatics, currently serving as a Senior Bioinformatics Scientist at Medicinal Genomics since December 2019. Prior roles include Senior Production Bioinformatician at Veritas Genetics, Scientist II at Agenus, and Scientific Project Manager and Genomics Scientist at Seven Bridges. McLaughlin also held the position of Senior Bioinformatics Scientist at Courtagen Life Sciences, Inc. and Senior Scientist at Applied Biosystems. Early career experience includes work as a Scientist at US Genomics and a Senior Research Technician at Dana Farber Cancer Institute. Educational credentials include a Master of Science in Bioinformatics from Boston University and a Bachelor of Science in Psychology/Neuroscience from the University of Massachusetts Amherst.
This person is not in any offices
Medicinal Genomics
Medicinal Genomics is pioneering the genomics of medical cannabis and hemp. In 2011, Medicinal Genomics made worldwide headlines for being the first group to decode the Cannabis Genome. An increasing amount of scientific evidence supports the theory that cannabinoid compounds may have numerous medical benefits. Medicinal Genomics has the largestDNA sequence database of the cannabis plant and is well-positioned to design fingerprinting assays for strain genotyping and sequencing services for strain development. In 2011, Medicinal Genomics was acquired by Courtagen Life Sciences, Inc.